Evaluation of RO7566802 Monotherapy and Combination with Atezolizumab in Locally Advanced or Metastatic Solid Tumor Malignancies

The primary objective of this study is to evaluate the **safety**, **tolerability**, **pharmacokinetics**, and **activity** of RO7566802 when administered alone and in combination with atezolizumab in patients with **locally advanced or metastatic solid tumors**. This is clinically relevant as it aims to determine the potential therapeutic benefits and risks associated with the treatment, which could inform future therapeutic strategies for managing these malignancies.

The clinical trial involves a total of **111 participants** diagnosed with **locally advanced or metastatic solid tumors**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. Participants were selected without targeting any vulnerable populations. The general health status of the participants is not specified, but they are likely to be individuals with a diagnosis of the specified medical condition. Lifestyle considerations such as diet, physical activity, or habits are not detailed in the available data. The selection process for the trial population is not explicitly described, and no specific inclusion or exclusion criteria are provided by the sponsor.

The clinical trial is designed to evaluate the **safety**, tolerability, pharmacokinetics, and activity of RO7566802, administered alone and in combination with atezolizumab, in patients with **locally advanced or metastatic solid tumors**. This study is a Phase 1 trial, characterized by a randomized, double-blind, and controlled design, ensuring the reliability and validity of the results. The trial is expected to commence recruitment on April 1, 2025, and is projected to conclude by April 27, 2026, marking the overall trial duration.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be enrolled and randomized into treatment groups. Subsequent follow-up visits will be scheduled at regular intervals to monitor the participants' response to the treatment, assess any adverse events, and ensure adherence to the study protocol. The end-of-study visit will occur upon completion of the treatment period, where final assessments will be conducted to evaluate the primary and secondary endpoints of the trial.

The expected length of participant involvement will span the entire duration of the trial, from the initial screening to the end-of-study visit. However, conditions such as significant adverse reactions, non-compliance with the study protocol, or withdrawal of consent may lead to early termination from the study. Participants will be closely monitored throughout the trial to ensure their safety and the integrity of the study data.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of these details limits the ability to describe the treatment regimen comprehensively.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is April 1, 2025, with an anticipated end date of April 27, 2026. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. These assessments may include the use of validated scales, laboratory tests, or patient-reported outcomes to measure changes in **biomarker** levels or symptom improvement. The schedule for measuring and collecting data is typically aligned with the trial's timeline, ensuring systematic data collection at predefined intervals. The analysis of efficacy data will be conducted using appropriate statistical methods to determine the potential therapeutic effects of the investigational product. The trial's design and methodology adhere to regulatory standards to ensure the reliability and validity of the findings.